The management of the RusnanoMedInvest Venture Fund has been outsourced to a company called RMI Partners, based on an agreement with RUSNANO.
RMI Partners is a global life sciences venture capital investment firm. It's investment strategy is a technology-, therapeutic-area-, clinical-context- and geography-agnostic. RMI Partners invests in exceptional early- to mid-stage life sciences opportunities with a potential to deliver genuinely step-change productivity, efficiency and effectiveness impact to the key healthcare stakeholders simultaneously, including patients, payers, caregivers, healthcare professionals and regulators.
More information www.rmivc.com
NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.
26 May 2017
26 May 2017